BIOLASE Statistics
Total Valuation
BIOLASE has a market cap or net worth of $4.78 million. The enterprise value is $13.03 million.
| Market Cap | 4.78M |
| Enterprise Value | 13.03M |
Important Dates
The next estimated earnings date is Thursday, May 9, 2024, after market close.
| Earnings Date | May 9, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
BIOLASE has 32.52 million shares outstanding. The number of shares has increased by 1,752.17% in one year.
| Shares Outstanding | 32.52M |
| Shares Change (YoY) | +1,752.17% |
| Shares Change (QoQ) | +8.40% |
| Owned by Insiders (%) | 0.34% |
| Owned by Institutions (%) | 8.24% |
| Float | 32.39M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.10 |
| Forward PS | 0.09 |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.27 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.26
| Current Ratio | 1.26 |
| Quick Ratio | 0.61 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -7.73 |
Financial Efficiency
Return on equity (ROE) is -1,012.40% and return on invested capital (ROIC) is -123.09%.
| Return on Equity (ROE) | -1,012.40% |
| Return on Assets (ROA) | -96.80% |
| Return on Capital (ROIC) | -123.09% |
| Revenue Per Employee | $313,146 |
| Profits Per Employee | -$239,611 |
| Employee Count | 157 |
| Asset Turnover | 1.27 |
| Inventory Turnover | 2.38 |
Taxes
In the past 12 months, BIOLASE has paid $31,000 in taxes.
| Income Tax | 31,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -99.41% in the last 52 weeks. The beta is 0.69, so BIOLASE's price volatility has been lower than the market average.
| Beta (1Y) | 0.69 |
| 52-Week Price Change | -99.41% |
| 50-Day Moving Average | 0.18 |
| 200-Day Moving Average | 2.27 |
| Relative Strength Index (RSI) | 38.87 |
| Average Volume (30 Days) | 5,659,269 |
Short Selling Information
The latest short interest is 2.29 million, so 7.06% of the outstanding shares have been sold short.
| Short Interest | 2.29M |
| Short Previous Month | 288,865 |
| Short % of Shares Out | 7.06% |
| Short % of Float | 7.08% |
| Short Ratio (days to cover) | 0.21 |
Income Statement
In the last 12 months, BIOLASE had revenue of $49.16 million and -$37.62 million in losses. Loss per share was -$29.44.
| Revenue | 49.16M |
| Gross Profit | 16.72M |
| Operating Income | -17.94M |
| Pretax Income | -20.60M |
| Net Income | -37.62M |
| EBITDA | -15.44M |
| EBIT | -18.24M |
| Loss Per Share | -$29.44 |
Balance Sheet
The company has $6.57 million in cash and $14.82 million in debt, giving a net cash position of -$8.25 million or -$0.25 per share.
| Cash & Cash Equivalents | 6.57M |
| Total Debt | 14.82M |
| Net Cash | -8.25M |
| Net Cash Per Share | -$0.25 |
| Equity / Book Value | -247,000 |
| Book Value Per Share | -0.01 |
| Working Capital | 5.20M |
Cash Flow
In the last 12 months, operating cash flow was -$14.09 million and capital expenditures -$1.13 million, giving a free cash flow of -$15.22 million.
| Operating Cash Flow | -14.09M |
| Capital Expenditures | -1.13M |
| Free Cash Flow | -15.22M |
| FCF Per Share | -$11.91 |
Margins
Gross margin is 34.02%, with operating and profit margins of -36.48% and -76.52%.
| Gross Margin | 34.02% |
| Operating Margin | -36.48% |
| Pretax Margin | -41.90% |
| Profit Margin | -76.52% |
| EBITDA Margin | -31.41% |
| EBIT Margin | -37.10% |
| FCF Margin | -30.96% |
Dividends & Yields
BIOLASE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 2 |
| Payout Ratio | n/a |
| Buyback Yield | -1,752.17% |
| Shareholder Yield | -1,752.17% |
| Earnings Yield | -787.41% |
| FCF Yield | -318.57% |
Analyst Forecast
The average price target for BIOLASE is $14.80, which is 9,974.88% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $14.80 |
| Price Target Difference | 9,974.88% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on July 28, 2023. It was a reverse split with a ratio of 1:100.
| Last Split Date | Jul 28, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:100 |
Scores
BIOLASE has an Altman Z-Score of -12.69 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -12.69 |
| Piotroski F-Score | 4 |